Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07457541 | Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI | active not recruiting | Phase 1 | 15 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07663487 | A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis. | not yet recruiting | Phase 2 | 78 | Sirtex Medical |
| 0 |
| Jun 25, 2026 |
| clinicaltrials |
| NCT07667608 | Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings | not yet recruiting | — | 120 | Assiut UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 36 | Hebei Medical University Fourth HospitalOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07669597 | Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in Sohag(HCC) | active not recruiting | — | 50 | Sohag Oncology CenterOTHER_GOV | 1 | Jun 25, 2026 | clinicaltrials |
| NCT01015833 | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 3 | 356 | National Cancer Institute (NCI)NIH | 3 | Jun 24, 2026 | clinicaltrials |
| NCT01715402 | Optimization of Health Expenditure in Liver Surgery | completed | — | 3,000 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02868255 | Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma(MDScan) | completed | — | 30 | Nantes University HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | terminated | Phase 2 | 43 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05497778 | A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | active not recruiting | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02156739 | Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions | active not recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT03991832 | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors(SOLID) | active not recruiting | Phase 2 | 58 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07207304 | Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes | completed | N/A | 153 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07664007 | Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma. | completed | N/A | 18 | Instituto de Investigación Sanitaria AragónOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02151084 | A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | active not recruiting | Phase 2 | 57 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04483726 | Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)(DIPLOMA) | completed | N/A | 9 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04727307 | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial(AB-LATE02) | active not recruiting | Phase 2 | 202 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05346536 | Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)(CTC-AXL-PANC) | recruiting | N/A | 63 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658833 | TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC | recruiting | — | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY | 26 | Jun 18, 2026 | clinicaltrials |
| NCT04616131 | Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy | recruiting | — | 500 | Northwestern UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06381154 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 24 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06971848 | Evaluation of Skin Tests in Biotherapy Allergies(ETCABIO) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656376 | Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 2 / Phase 3 | 465 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07657273 | Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07658105 | Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI(Ad-rHCC) | active not recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02600949 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | enrolling by invitation | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function | terminated | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03132792 | AFPᶜ³³²T in Advanced HCC | completed | Phase 1 | 39 | AdaptimmuneINDUSTRY | 4 | Jun 17, 2026 | clinicaltrials |
| NCT05486572 | Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI(PREMIUM) | recruiting | N/A | 4,700 | VA Office of Research and DevelopmentFED | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06600321 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | recruiting | Phase 1 | 158 | Alnylam PharmaceuticalsINDUSTRY | 3 | Jun 17, 2026 | clinicaltrials |
| NCT06636435 | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | recruiting | Phase 1 | 66 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06925516 | A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC(ACADEMY) | recruiting | Phase 2 | 38 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT00554372 | A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 30 | Jennerex BiotherapeuticsINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT03269526 | BATs Treatment for Pancreatic Cancer, Phase Ib/II | completed | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03307408 | Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease(CHALNA) | completed | — | 180 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04829383 | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma(AB7) | completed | Phase 2 | 6 | Howard S HochsterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05038254 | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events | active not recruiting | N/A | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05657743 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety) | recruiting | N/A | 15 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06026943 | Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer | recruiting | N/A | 15 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2026source: clinicaltrials